COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7-8% organic sales growth with an adjusted EBITDA margin at the higher end of the 37-38% range.
Ester Baiget, President & CEO:
“With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis’ diversified business. Our ability to combine leading scientific biosolutions capabilities with a broad market reach, positions us well to address evolving customer needs and unlock more growth opportunities. We remain confident in our full-year outlook, supported by a solid start to the fourth quarter.”
Highlights of our 9M 2026 results:
Here is the link to the investor call on Novonesis' 9M 2026 results on November 5, 2026 at 9:00 CET: Novonesis 9M 2026 Results
Media relations
Benjamin Hjorth
Senior Press Manager
media-relations@novonesis.com +45 30 77 13 12
Tobias Bjorklund
Head of Investor Relations
tobb@novonesis.com